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No reason to change WHO guidelines on cleansing the 
umbilical cord
20 years ago, neonatal survival was not on the global 
health agenda. In many low-income settings, infants 
died without recognition, causing untold grief. However, 
the past two decades have seen steady improvements in 
neonatal survival on a background of sustained advocacy, 
a culture of community-based trials, and improvements 
in quantity and quality of health care, health behaviour, 
and demand for services. Nevertheless, an annual 
2·7 million newborn babies still do not survive their ﬁ rst 
month of life.1 Focusing on one intervention to address 
this issue, two African trials in The Lancet Global Health2,3 
tested umbilical cord cleansing with antiseptic solution. 
Supporting evidence to date has come from randomised 
controlled trials in south Asia, which suggested that 
cleansing with chlorhexidine solution could reduce both 
periumbilical inﬂ ammation (omphalitis) and neonatal 
mortality.4–6 In a previous Comment7 we suggested that 
the putative eﬀ ects might diminish at scale, that it would 
be good for families to do the cord cleansing themselves, 
and that evidence from high-mortality populations in 
Africa would be helpful. In the interim, a meta-analysis8 
estimated the combined risk ratio (RR) for neonatal 
mortality at 0·77 (95% CI 0·63–0·94).
Katherine Semrau and colleagues2 did a cluster-
randomised controlled trial in Southern Province, 
Zambia. Fieldworkers visited women antenatally within 
24 h of delivery, and repeatedly during the newborns’ 
ﬁ rst month of life. Families in the intervention group 
were given 4% chlorhexidine solution to apply 
10 mL, using eyedropper bottles, once per day until 
cord separation, whereas families in the control group 
were encouraged to maintain dry cord care. Semrau 
and colleagues2 reported no diﬀ erence between 
allocation groups in the primary outcome of neonatal 
mortality rate (deaths [in the ﬁ rst 28 days post-partum] 
per 1000 livebirths; RR 1·12, 95% CI 0·88–1·44) or 
the secondary outcome of occurrence of omphalitis 
(diagnosed by erythema or purulent discharge; 0·73, 
0·47–1·13). 
Sunil Sazawal and colleagues3 did a community-
based, individually-randomised controlled trial in 
Pemba Island, Tanzania. Maternal–child health workers 
visited on the day of delivery and days 1, 4, 10, and 28; 
showed families how to care for the cord; and gave them 
4% chlorhexidine solution to apply once per day, using 
10 mL dropper bottles, until cord separation. The trial3 
began with three comparison groups—dry cord care, 
chlorhexidine treatment group, or control group using a 
placebo solution—but the control group was dropped in 
the second phase of the study. Sazawal and colleagues3 
reported no diﬀ erence between allocation groups in 
Figure: Log odds of neonatal mortality associated with chlorhexidine cord cleansing, by proportion of home 
deliveries in control group (A) and neonatal mortality in control group (B) 
Data are from published ﬁ ndings of ﬁ ve trials.2–6 Circles=point estimates of log odds. Bars=conﬁ dence intervals. 
Triangles=prediction including random eﬀ ects. Shaded area=meta-regression CI.
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neonatal mortality rates (RR 0·90, 95% CI 0·74–1·09), 
but babies in the chlorhexidine group had a lower risk of 
omphalitis than those in the dry cord care group (0·65, 
0·61–0·70). Design and randomisation methods diﬀ ered 
between the two studies, but follow-up was exceptionally 
successful: almost 100% of babies at 28 days in Zambia2 
and 97% in Tanzania.3 On a spectrum of eﬃ  cacy, the 
trials were pitched toward real-world conditions. The 
interventions were delivered by project staﬀ , but mothers 
were encouraged to apply the treatment themselves. 
Whether or not they did so—and it seems likely that 
they did (98% compliance was reported in the Zambia 
study2)—it was an intention-to-treat approach.
Two important issues aﬀ ect our interpretation of 
these ﬁ ndings. First, many women chose institutional 
delivery (53% of deliveries were at hospitals in Sazawal 
and colleagues’ trial, and 64% in Semrau and colleagues’ 
trial2). The latest WHO guidelines9 recommend 
application of chlorhexidine to the umbilical cord 
stump for the ﬁ rst week after birth, for infants born at 
home in environments with high neonatal mortality 
rates (>30 deaths per 1000 livebirths). Dry cord care 
is recommended after institutional births or home 
births in settings with lower neonatal mortality rates.9 
Chlorhexidine might be considered as a replacement for 
harmful applications to the cord stump,9 but Cochrane 
reviews, a meta-analysis,8 and these two new trials2,3 
have not supported an eﬀ ect after hospital births.10,11 
Second, the neonatal mortality rates were lower 
than expected. The sample size for the Zambian 
study2 was developed on the assumption that the 
neonatal mortality rate in the control group would 
be 29·0 deaths per 1000 livebirths. However, the 
observed rate was 14·4 deaths per 1000 livebirths. The 
Tanzanian study3 assumed a control group neonatal 
mortality rate of 31 deaths per 1000 livebirths. The 
observed neonatal mortality rate was 11·7 deaths per 
1000 livebirths. Both trials increased their sample 
sizes during implementation, yet conﬁ dence intervals 
around estimates of eﬀ ects on neonatal mortality rates 
were nevertheless substantial. To address the issue of 
underpowering, the research groups combined their 
estimates in a random-eﬀ ects meta-analysis, resulting 
in a relative risk estimate of 0·99 (95% CI 0·80–1·23) for 
neonatal mortality by day 28. 
The three major drivers of newborn mortality are 
infection, preterm birth, and presumed intrapartum-
related compromise. The implicit assumption is that 
antiseptic cleansing will prevent microbial invasion and 
reduce deaths from infection. However, as neonatal 
mortality rates decrease, the proportion of deaths 
explained by infection reduces in relation to the other 
two causes. What this means is that the yield in terms 
of reduction in all-cause mortality as a result of cord 
antisepsis is likely to be lower in settings with low 
neonatal mortality rates. To test our assumption, we 
used the published ﬁ ndings of the ﬁ ve trials2–6 as a basis 
for conservative meta-regression. The ﬁ gure shows 
the reduction in mortality associated with varying 
proportions of home delivery and neonatal mortality 
rates. Although not signiﬁ cant, the impression is 
that higher neonatal mortality rates (p=0·109) and a 
higher proportion of home deliveries (p=0·138) were 
associated with larger eﬀ ects of cord cleansing on 
neonatal mortality rates.
Along with the individual trial ﬁ ndings, the ﬁ gure 
is consonant with the current WHO guidelines9 
for cord care, to which we recommend no change. 
Cord cleanliness is part of the suite of hard-won 
improvements that accompany the increases in 
survival being seen worldwide. In settings in which 
neonatal mortality rates remain high, we recommend 
the kinds of programme that have been associated 
with reductions in all-cause mortality. These include 
improvements in institutional quality of care and 
eﬀ orts to improve community-based practices, both 
central to the 2014 Every Newborn Action Plan.12
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